These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 10393535)

  • 1. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
    Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
    Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
    Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
    Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
    Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
    Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA binding properties of the indolocarbazole antitumor drug NB-506.
    Carrasco C; Vezin H; Wilson WD; Ren J; Chaires JB; Bailly C
    Anticancer Drug Des; 2001; 16(2-3):99-107. PubMed ID: 11962518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle.
    Moreau P; Anizon F; Sancelme M; Prudhomme M; Bailly C; Carrasco C; Ollier M; Sevère D; Riou JF; Fabbro D; Meyer T; Aubertin AM
    J Med Chem; 1998 May; 41(10):1631-40. PubMed ID: 9572888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
    Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
    J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
    Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
    Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
    Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
    J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
    Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
    Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
    Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
    J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
    Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG
    Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin.
    Woo MH; Vance JR; Marcos AR; Bailly C; Bjornsti MA
    J Biol Chem; 2002 Feb; 277(6):3813-22. PubMed ID: 11733535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents.
    Bailly C; Dassonneville L; Colson P; Houssier C; Fukasawa K; Nishimura S; Yoshinari T
    Cancer Res; 1999 Jun; 59(12):2853-60. PubMed ID: 10383146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition.
    Bailly C; Qu X; Graves DE; Prudhomme M; Chaires JB
    Chem Biol; 1999 May; 6(5):277-86. PubMed ID: 10322124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
    Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
    Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A DNA binding indolocarbazole disaccharide derivative remains highly cytotoxic without inhibiting topoisomerase I.
    Qu X; Chaires JB; Ohkubo M; Yoshinari T; Nishimura S; Bailly C
    Anticancer Drug Des; 1999 Oct; 14(5):433-42. PubMed ID: 10766298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
    Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
    Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
    Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
    Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indolocarbazole glycosides in inactive conformations.
    Facompré M; Carrasco C; Vezin H; Chisholm JD; Yoburn JC; Van Vranken DL; Bailly C
    Chembiochem; 2003 May; 4(5):386-95. PubMed ID: 12740810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity.
    Labourier E; Riou JF; Prudhomme M; Carrasco C; Bailly C; Tazi J
    Cancer Res; 1999 Jan; 59(1):52-5. PubMed ID: 9892183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.